You can’t scrub plaque out of your arteries like cleaning a pipe, but you can shrink it, stabilize it, and in some cases partially reverse it. Plaque regression is real and measurable. Clinical trials using imaging inside coronary arteries have documented reductions in plaque volume with aggressive cholesterol lowering, and intensive lifestyle changes have produced regression on their own. The key is understanding what’s realistic: even the most effective treatments reduce plaque volume by a few percentage points, not back to zero. But that modest shrinkage, combined with changes in plaque composition that make it far less likely to rupture, translates into significantly fewer heart attacks and strokes.
What Arterial Plaque Actually Is
Plaque isn’t a simple blockage like grease in a drain. It’s a complex structure embedded in the artery wall, built up over years from cholesterol, immune cells, calcium, and scar tissue. The real danger isn’t usually the size of the plaque but its stability. A plaque with a large pool of soft, fatty material covered by a thin cap (less than 65 micrometers thick, roughly the width of a human hair) can rupture suddenly, triggering a blood clot that causes a heart attack. A plaque with a thick, fibrous cap and less fatty material inside is far less dangerous, even if it’s the same size.
This distinction matters because many of the most effective treatments work by changing what plaque is made of, not just how big it is. They shrink the fatty core, thicken the protective cap, and reduce the inflammation that destabilizes the whole structure. That’s why cardiologists talk about plaque “stabilization” as much as plaque “regression.” Both protect you.
How Your Body Removes Cholesterol Naturally
Your body has a built-in system for pulling cholesterol out of cells, including the ones lining your artery walls. HDL particles (often called “good cholesterol”) act as the transport vehicles. They pick up excess cholesterol from cells, carry it through the bloodstream to the liver, and the liver processes it for disposal. This process, called reverse cholesterol transport, is the primary biological mechanism behind plaque regression. When treatments lower LDL cholesterol aggressively, they tip the balance so that more cholesterol leaves the artery wall than enters it, allowing plaques to slowly shrink.
Lowering LDL: The Most Proven Approach
The single most effective strategy for shrinking plaque is driving LDL cholesterol (“bad cholesterol”) as low as possible. The relationship is direct and dose-dependent: the lower your LDL goes, the more plaque regresses. The latest guidelines from the American College of Cardiology and American Heart Association (published 2026) recommend an LDL target below 55 mg/dL for people at very high risk of cardiovascular events, such as those who’ve already had a heart attack or have extensive coronary calcium.
High-intensity statin therapy is the foundation. Landmark trials found that high-dose statins reduce plaque volume by about 1% over two years. That sounds small, but these trials also showed that statins reshape the artery itself, smoothing out the inner lining and reducing the mechanical stress on plaques that leads to rupture. Beyond shrinkage, statin-treated plaques develop more dense, calcified tissue (which is stable) and less soft, fatty tissue (which is dangerous).
For people who need LDL levels lower than statins alone can achieve, adding a PCSK9 inhibitor produces further regression. In the GLAGOV trial, adding a PCSK9 inhibitor to statin therapy reduced plaque volume by about 1% in patients with stable disease. In patients treated after a heart attack (the HUYGENS trial), the combination produced a 2.3% reduction in plaque volume in just 12 months, along with favorable changes in plaque composition. The greater regression in post-heart attack patients likely reflects their higher starting plaque burden (about 46% of the artery filled with plaque, compared to 36% in the stable group) and the more active, inflamed state of their plaques.
Other cholesterol-lowering medications can be layered on as well. The general principle from guidelines is that for people with significant coronary calcium or established heart disease, the goal is at least a 50% reduction in LDL from baseline, with absolute targets as low as 55 mg/dL.
How Lifestyle Changes Affect Plaque
The Lifestyle Heart Trial was the first randomized, controlled study to show that coronary artery disease could regress with lifestyle changes alone, no medications. Participants followed an intensive program: a vegetarian diet with only about 10% of calories from fat, moderate aerobic exercise, stress management training, smoking cessation, and group support. After one year, angiography showed measurable regression in the arteries of participants who stuck with the program, while the control group’s disease progressed.
The program was deliberately extreme, far more restrictive than what most doctors recommend today. But it established an important principle: the artery wall responds to the same cholesterol-lowering logic whether you achieve it through diet or drugs. Reducing the amount of cholesterol entering the bloodstream from food, increasing the body’s ability to clear it, and lowering inflammation all contribute.
Exercise and Plaque Stability
Exercise affects plaque in ways that go beyond cholesterol numbers. A study using near-infrared spectroscopy to look inside coronary arteries found that after six months, both high-intensity interval training and standard exercise programs reduced lipid content within plaques by 13% to 14%. There was no significant difference between the two exercise intensities, but a secondary analysis combining both groups found that the fitter someone became, the more their plaque lipid content dropped. The correlation was moderate but consistent: improving your cardiovascular fitness by any method appears to make plaques less fatty and more stable.
Exercise also lowers blood pressure, improves blood sugar control, reduces inflammation, and raises HDL, all of which slow plaque growth and promote the conditions needed for regression.
The Role of Inflammation
Cholesterol drives plaque growth, but inflammation is what makes plaque dangerous. Inflamed plaques attract immune cells that weaken the fibrous cap, increasing the risk of rupture. Targeting inflammation directly has become a major focus in cardiology.
The CANTOS trial tested a medication that blocks a specific inflammatory signaling molecule (interleukin-1β) in over 10,000 patients with stable heart disease who were already on statins. Higher doses reduced major cardiovascular events by 15%, and the benefit tracked directly with how much inflammation decreased in each patient’s bloodstream. A separate trial, COLCOT, found that colchicine (a low-cost anti-inflammatory) reduced cardiovascular events by 23% over two years in patients recovering from a heart attack. Colchicine works partly by dampening the same inflammatory cascade, reducing levels of key inflammatory markers.
Importantly, not all anti-inflammatory approaches work. The CIRT trial tested low-dose methotrexate (a different type of anti-inflammatory) and found no benefit, likely because it didn’t reduce the specific inflammatory signals, interleukin-1β, interleukin-6, and C-reactive protein, that drive plaque instability. This tells us that it’s not generic inflammation reduction that matters, but hitting the right pathway.
When Plaque Is Physically Removed
In specific situations, plaque can be surgically removed. The most common procedure is carotid endarterectomy, where a surgeon opens the carotid artery in the neck and removes the plaque directly. This is primarily done for people who’ve had symptoms like a transient ischemic attack (mini-stroke) or mild stroke and have 70% or greater narrowing of the carotid artery. For people without symptoms, surgery may be considered when narrowing exceeds 60%, though the threshold requires a very low complication rate (under 3%) to justify the procedure.
In the coronary arteries (the ones feeding the heart), plaque isn’t typically removed. Instead, stents are placed to hold the artery open, or bypass surgery reroutes blood around blocked segments. These procedures address severe blockages that limit blood flow or threaten imminent heart attack, but they don’t change the underlying disease process. That’s why medication and lifestyle changes remain essential even after a procedure.
How Plaque Is Measured and Monitored
If you’re wondering whether your efforts are working, the most common way to assess plaque burden outside of a hospital is a coronary artery calcium (CAC) score, a quick CT scan that quantifies calcified plaque in your heart’s arteries. Among available noninvasive tests, CAC scoring provides the best ability to discriminate cardiovascular risk, particularly for people at intermediate risk. It outperforms carotid ultrasound (which measures artery wall thickness) in predicting heart attacks and strokes, and it’s more reproducible between different technicians and facilities.
Your CAC score directly influences treatment targets. A score of 100 to 299 calls for an LDL goal below 70 mg/dL. A score of 300 or higher, or 1,000 or higher, pushes the target to below 55 mg/dL, the same aggressive goal used for people who’ve already had a cardiac event. A score of zero, on the other hand, suggests very low near-term risk and may mean you can defer or reduce medication.
One caveat: CAC scores can actually increase in the short term with statin therapy, because statins convert soft, unstable plaque into denser, calcified plaque. A rising CAC score during treatment doesn’t necessarily mean your disease is worsening. It can mean your plaques are becoming more stable. This is why doctors interpret CAC scores in context rather than as a simple “higher is worse” metric during treatment.
A Realistic Timeline
Plaque didn’t build up overnight, and it won’t disappear quickly. Measurable regression in clinical trials typically takes 12 to 24 months of sustained, aggressive treatment. The HUYGENS trial showed meaningful changes at 12 months. Most statin trials assess results at 24 months. Lifestyle-based regression in the Lifestyle Heart Trial was documented at one year, with continued improvement at five years for those who maintained the program.
The practical takeaway: if you’re combining cholesterol-lowering medication with regular exercise, a diet low in saturated fat, and management of blood pressure and blood sugar, you’re engaging every mechanism known to slow, stabilize, and partially reverse plaque. Complete elimination of plaque isn’t a realistic goal, but reducing your risk of a cardiac event by transforming dangerous plaque into stable plaque is both achievable and well-supported by evidence.